Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Coherus Oncology (NASDAQ:CHRS) from a sell rating to a hold rating in a report published on Saturday.

Separately, Oppenheimer started coverage on shares of Coherus Oncology in a research report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $5.51.

Coherus Oncology Price Performance

Shares of CHRS stock opened at $1.66 on Friday. The firm has a market cap of $248.82 million, a P/E ratio of 1.14 and a beta of 1.04. Coherus Oncology has a fifty-two week low of $0.71 and a fifty-two week high of $2.62. The business’s 50 day moving average price is $1.81 and its 200-day moving average price is $1.57. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.45 and a current ratio of 1.47.

Coherus Oncology (NASDAQ:CHRS) last posted its earnings results on Monday, March 9th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Coherus Oncology had a net margin of 398.42% and a negative return on equity of 860.29%. The business had revenue of $12.75 million for the quarter, compared to analysts’ expectations of $14.09 million. On average, equities research analysts anticipate that Coherus Oncology will post -1.05 earnings per share for the current year.

Institutional Trading of Coherus Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Panagora Asset Management Inc. purchased a new position in Coherus Oncology during the 2nd quarter valued at about $581,000. Tejara Capital Ltd grew its holdings in Coherus Oncology by 1.7% in the second quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock worth $511,000 after purchasing an additional 11,552 shares during the period. Quarry LP bought a new position in shares of Coherus Oncology during the third quarter valued at approximately $26,000. ProShare Advisors LLC lifted its holdings in shares of Coherus Oncology by 36.3% during the fourth quarter. ProShare Advisors LLC now owns 24,718 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 6,583 shares during the last quarter. Finally, Jefferies Financial Group Inc. lifted its holdings in shares of Coherus Oncology by 21.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 395,190 shares of the biotechnology company’s stock valued at $561,000 after purchasing an additional 69,565 shares during the last quarter. 72.82% of the stock is owned by hedge funds and other institutional investors.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.